Filter Releases
 
News Releases
Date Title and Summary View
Jun 19, 2002
TUSTIN, Calif., Jun 19, 2002 (BW HealthWire) --Tumor Necrosis Therapy Data Presented at Society of Nuclear Medicine's 49th Annual Meeting Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced today detailed results from clinical research conducted in China that show 56% efficacy was achieved when patients with inoperable lun...
Jun 18, 2002
TUSTIN, Calif., Jun 18, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) today announced the issuance of U.S. Patent No. 6,406,693 covering new methods for treating vascularized tumors using antibodies that bind to a particular group of lipids, termed aminophospholipids, specific markers of tumor blood vessels. The patent was iss...
Jun 17, 2002
TUSTIN, Calif., Jun 17, 2002 (BW HealthWire) -- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced the issuance of U.S. Patent No. 6,403,096 covering the use of Permeability Enhancing Peptide (PEP) as a Vasopermeation Enhancement Agent (VEA). The patent, entitled "Vasopermeability Enhancing Peptide of Human Interleukin-2 and Imm...
Jun 13, 2002
TUSTIN, Calif., Jun 13, 2002 (BW HealthWire) --Peregrine's Novel Vascular Targeting Agent Shows Significant Anti-Cancer Activity in Pre-Clinical Studies Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today introduced a new type of Vascular Targeting Agent (VTA) at the First International Conference on Vascular Targeting in Camb...
Jun 11, 2002
BIOWIRE2K TUSTIN, Calif.--(BW HealthWire)--June 11, 2002-- Preclinical Study was Conducted At M.D. Anderson and the University of Texas Southwestern Medical Center At Dallas; Results to be Published in Today's Proceedings of the National Academy of Sciences Human Clinical S...
Jun 10, 2002
TUSTIN, Calif., Jun 10, 2002 (BW HealthWire) --Events Recognize Vascular Targeting Agents as New Class of Cancer Therapeutics Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center, is presenting an overview of Pere...
May 21, 2002
TUSTIN, Calif., May 21, 2002 (BW HealthWire) --Pre-Clinical Data Demonstrates VEA Can Substantially Increase the Efficacy of Some Chemotherapeutic Drugs for the Treatment of Solid Tumors Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) announced that Alan L. Epstein, M.D., Ph.D hosted a poster presentation and discussion session ...
May 14, 2002
TUSTIN, Calif., May 14, 2002 (BW HealthWire) --Major Milestone Reached in Development of TNT Imaging and Diagnostic Agents Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) announced today that in an article published in the journal Hybridoma and Hybridomics, researchers described how they successfully generated stable fragments...
May 7, 2002
TUSTIN, Calif., May 7, 2002 (BUSINESS WIRE) -- The North American Brain Tumor Coalition (NABTC), a network of advocacy organizations, sponsors Brain Tumor Action Week May 5-11 in order to promote awareness of brain tumors and campaign for the development and funding of innovative treatment options. According to the NABTC, each year more th...
May 7, 2002
TUSTIN, Calif., May 7, 2002 (BW HealthWire) --Data to be Presented At Society of Nuclear Medicine's 49th Annual Meeting, June 15-19, 2002 Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that interim data from human clinical studies using Peregrine's proprietary Tumor Necrosis Therapy (TNT) technology will be pre...
May 7, 2002
May 07, 2002 (BUSINESS WIRE) --In BW2235, (CA-PEREGRINE-PHARM-2) Peregrine Pharmaceuticals Announces Abstracts of Interim Results, fifth graph, sixth line should read xxx greater than 50% (sted less than 50%) and eighth line should read xxx greater than 10 weeks (sted less than 10 weeks.) CONTACT: Atkins + Associ
May 6, 2002
TUSTIN, Calif., May 6, 2002 (BUSINESS WIRE) -- In an effort to promote awareness of brain tumors and advocate the development and funding of innovative treatment options, Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) is sponsoring today's Brain Tumor Action Week Education Day. Education Day activities, held at the Hotel Washington in Washin...
Apr 9, 2002
TUSTIN, Calif., Apr 9, 2001 (BW HealthWire) --Research Presented in Multiple Abstracts Extends Functions of Anticancer Technologies Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that two of its founding scientists are chairing a poster discussion session and presenting nine abstracts in poster and oral present...
Mar 19, 2002
TUSTIN, Calif.,, Mar 19, 2002 (BW HealthWire) -- Avid Bioservices Inc. (Avid), a wholly owned subsidiary of Peregrine Pharmaceuticals (Nasdaq:PPHM), today announced that it has finalized a manufacturing supply agreement with Inhibitex Inc. of Atlanta, for the production of therapeutic monoclonal antibodies for use in future clinical studies. ...
Mar 18, 2002
TUSTIN, Calif.--(BW HealthWire)--March 18, 2002--Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) today announced that it will conduct its quarterly conference call on Thursday, March 21 at 11 a.m. (ET). In order to participate in this call, phone 800/274-0251 at least five minutes before the call is scheduled to begin. An ...
= add release to Briefcase

Search Investor Relations